Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- Takeda Taps Ex-Kraft Foods CFO Kehoe as New CFO
May 13, 2016
- Daiichi Sankyo CEO Sees High Odds of Success for AML Drug Quizartinib
May 13, 2016
- Daiichi Sankyo Sees 7.3% Sales Rise, but Girding for FY2016 Dip on Olmesartan Cliff
May 13, 2016
- Kissei Ditches Constipation Drug KWA-0711, Turns to Other Products for GI Entry
May 13, 2016
- Nichi-Iko to Develop 3 Biosimilars for Global Market, Aims to Enter as Global Top-10 Generic Maker within 3 Years
May 13, 2016
- Santen’s FY2015 Profits Zoom on Sale of RA Business
May 13, 2016
- Astellas Unveils List of Approval Hopefuls in FY2016
May 12, 2016
- Astellas Looking at Japan Filing of Romosozumab by March 2017
May 12, 2016
- Under New Name, Ocata Positioned as R&D Hub for Regenerative Medicine, Ophthalmology: Astellas
May 12, 2016
- Sumitomo Dainippon’s Sales Cross 400 Billion Yen as Latuda Becomes Blockbuster in N. America
May 12, 2016
- Shionogi Scores Record Operating Profit as Royalties Spike
May 12, 2016
- Mitsubishi Tanabe’s Sales Rise on Royalty, Upfront Revenues
May 12, 2016
- Baxalta Sues Chugai over Hemophilia A Drug Patent
May 12, 2016
- Ono Delivers Record Sales on Buoyant Opdivo, FY2016 Outlook Tops 250 Billion Yen
May 12, 2016
- Astellas Logs Record Earnings on Bullish Xtandi in FY2015
May 12, 2016
- Entyvio on Track to Rake in US$2 Billion in FY2018, Ninlaro Eyed as Next Big Seller
May 11, 2016
- Takeda Drops Diabetic Nephropathy Drug amid Change in R&D Strategy
May 11, 2016
- Takeda Enjoys Higher Revenues and Profits as Entyvio Sales Triple
May 11, 2016
- Meiji Seika Pharma Jettisons BPH Treatment
May 11, 2016
- AZ Set to Double Japan Sales by 2020 on Cancer Meds, No Patent Cliff in Sight: Local Pres. Baertschi
May 11, 2016
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…